Just One Shot
A vaccine using mRNA demonstrates potential for broad influenza protection
Stephanie Sutton |
A universal flu vaccine is on the agenda for a research team at the Perelman School of Medicine at the University of Pennsylvania. The team has developed a vaccine that uses mRNA molecules formulated in lipid nanoparticles (mRNA-LNPs) that encode HA proteins to create a strong antibody response.
“Today’s flu vaccine is about 60 percent effective, on average, and has to be reformulated every year. This is not really good enough given that flu causes extensive disease and significant mortality,” says Drew Weissman, a professor of infectious disease at the university and co-author of the study. “We are hoping to develop a better vaccine. Two things need to be improved; the first is efficacy and the second is durability of protection. We believe that a modified mRNA-LNP vaccine can do both.”
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine